Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met
Scilex Holding Company (SCLX)
Company Research
Source: GlobeNewswire
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced ZTlido® has reached three major milestones since it launched in October 2018. The following three milestones are a testament to the perceived confidence that patients and health care providers have in ZTlido®: Over one million patients are estimated to have been treated with ZTlido® since its launch according to Symphony Health prescription data.ZTlido® is now the number one prescribed non-opioid branded pain medication by pain specialists in the United States, based on Symphony Health prescription data gathered from January 2023 to November 2023.Patients report 89% satisfaction with ZTlido®, in a 2023 patient survey conducted by Scilex (n=100, rating as “completely”
Show less
Read more
Impact Snapshot
Event Time:
SCLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCLX alerts
High impacting Scilex Holding Company news events
Weekly update
A roundup of the hottest topics
SCLX
News
- Scilex Holding (NASDAQ: SCLX) had its price target lowered by analysts at HC Wainwright from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Scilex Holding Company Announces Closing of $15 Million Registered Direct OfferingGlobeNewswire
- Scilex Holding Company Announces $15 Million Registered Direct OfferingGlobeNewswire
- Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other AdGlobeNewswire
- Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing PoolGlobeNewswire
SCLX
Earnings
- 11/14/23 - Miss
SCLX
Sec Filings
- 4/25/24 - Form SC
- 4/25/24 - Form 424B3
- 4/25/24 - Form 424B3
- SCLX's page on the SEC website